{"id":"NCT02747043","sponsor":"Amgen","briefTitle":"Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab","officialTitle":"A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared With Rituximab in Subjects With CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-05-25","primaryCompletion":"2019-06-28","completion":"2019-06-28","firstPosted":"2016-04-21","resultsPosted":"2020-08-18","lastUpdate":"2022-09-10"},"enrollment":256,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma, Non-Hodgkin"],"interventions":[{"type":"BIOLOGICAL","name":"ABP 798","otherNames":["biosimilar to rituximab"]},{"type":"BIOLOGICAL","name":"Rituximab","otherNames":["Rituxan"]}],"arms":[{"label":"ABP 798","type":"EXPERIMENTAL"},{"label":"Rituximab","type":"ACTIVE_COMPARATOR"}],"summary":"This was a randomized, double-blind, active-controlled, multiple-dose, clinical similarity study to evaluate the efficacy, pharmacokinetics, pharmacodynamics, safety, tolerability and immunogenicity of ABP 798 compared with rituximab in subjects with grade 1, 2, or 3a follicular B-cell NHL and low tumor burden.\n\nSubjects were randomized in a 1:1 ratio to receive a 375 mg/m\\^2 intravenous infusion of either ABP 798 or rituximab once weekly for 4 weeks followed by dosing at weeks 12 and 20.","primaryOutcome":{"measure":"Percentage of Participants Who Responded (Overall Response Rate - ORR) by Week 28 Based on Independent Central Assessment of Disease","timeFrame":"Post treatment up to Week 28","effectByArm":[{"arm":"ABP 798","deltaMin":78,"sd":null},{"arm":"Rituximab","deltaMin":70.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":8},"locations":{"siteCount":98,"countries":["United States","Australia","Bulgaria","Canada","Colombia","Czechia","France","Georgia","Germany","Greece","India","Israel","Italy","Japan","Mexico","Poland","Romania","South Korea","Spain","Ukraine"]},"refs":{"pmids":["33044684"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":128},"commonTop":["Headache","Fatigue","Nausea","Asthenia","Pruritus"]}}